通过USP33调节的c-Myc稳定驱动糖分类重编程,并促进卵巢癌的进展
Dejia Chen1, Yue Zhao1, Xiaobo Zhang2
1Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.
Biochimica et biophysica acta. General subjects
|June 18, 2025
概括
德乌比奎丁酶USP33稳定c-Myc,驱动卵巢癌 (OC) 糖解和恶性病变. 准USP33-c-Myc通路为OC治疗提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 卵巢癌 (OC) 是一种致命的妇科恶性瘤,预后不佳.
- 脱化酶 (DUB) 与癌症的发展和代谢重编程有关.
- 在OC中确定新的治疗点仍然是一个至关重要的未满足的需求.
研究的目的:
- 为了调查duebiquitinaseUSP33在卵巢癌 (OC) 中的作用.
- 阐明USP33调节OC中的c-Myc稳定性和细胞代谢的机制.
- 评估USP33-c-Myc轴作为OC的预后生物标志物和治疗标的潜力.
主要方法:
- 定量PCR (qPCR) 和西部斑点分析以评估USP33表达.
- 功能性测试 (例如,扩散,迁移,入侵,亡) 来确定USP33在OC中的作用.
- 代谢试验评估USP33对糖解的影响.
- 同免疫沉和无处不在的测试,以调查USP33-c-Myc相互作用.
- 过度表达研究证实了USP33-c-Myc轴的作用.
主要成果:
- 在OC组织和细胞系中,USP33被显著上调.
- 通过USP33 Knockdown抑制OC细胞的增殖,迁移和入侵,同时促进细胞亡.
- 通过降低LDHA,GLUT1和PKM2的调节,USP33静音降低了葡萄糖吸收,乳酸生产和糖解.
- USP33直接对c-Myc进行双化和稳定,增强其转录活性.
- 过度表达c-Myc拯救了USP33对糖解和OC表型的敲击效应.
- 高USP33表达与患者预后不佳相关.
结论:
- USP33通过促进c-Myc-依赖的糖溶性重编程,在卵巢癌的发病过程中发挥着关键作用.
- USP33-c-Myc轴是OC恶性瘤的一个关键驱动因素.
- USP33代表了潜在的预后生物标志物和卵巢癌的有希望的治疗标.
关键词:
这就是C-Mycc.消灭城市的消灭.葡萄糖溶解是什么? 葡萄糖溶解代谢重编程是一种代谢重编程.卵巢癌是发生在卵巢中的癌症.SP3333 SP3333 SP3333 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP33 SP3 SP33 SP33 SP33 SP33 SP3 SP33 SP33 SP33 SP3 SP33 SP33 SP33 SP3 SP33 SP33 SP3 SP33 SP33 SP3 SP33 SP33 SP3 SP33 SP33 SP33 SP33
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:06Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:23Negative Regulator Molecules
36.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.2K
02:39Positive Regulator Molecules
5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K